Shudong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shudong Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Peter M. Fischer
School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK
3 shared publications Frankie Lam
School of Pharmacy and Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
2 shared publicationsHui Mao
Zhejiang University
1 shared publication- Nikolai Zhelev
CMCBR, School of Science, Engineering & Technology, Abertay University, Dundee, UK
1 shared publication Scott Roberts
University of Nottingham
1 shared publicationShenhua Shi
University of Nottingham
1 shared publication
Latest Publications
- 14 October 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (5) , 1899-1907
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities
ZJU-6 was designed to enhance anti-angiogenesis and anti-tumour activity of its parent compound Erianin, a clinic anti-tumour agent. This study investigated the detailed biological mechanism of ZJU-6 in comparison with that of Erianin. Both ZJU-6 and Erianin substantially reduced cell viability and induced apoptosis in human cancer cell lines. Profound G2/M cell arrest was observed 24 h after treatment of MCF-7 cells with ZJU-6 (≥ 2.5 μM) or Erianin (≥ 0.1 μM); being consistent with mitotic collapse. 0.5 μM of Erianin or ZJU-6 failed to stabilise tubulin. Pre-G1 MCF-7 cell accumulating 24 h post treatment indicated apoptosis. Caspase-3 activity, PARP cleavage and Annexin V + ve /PI -ve populations correlate the apoptotic destiny of cells exposed to either ZJU-6 or Erianin. Furthermore ZJU-6 showed potent anti-angiogenetic property and demonstrated radical scavenging capacity. Due to its potent anti-proliferative, pro-apoptotic and anti-angiogenic activities ZJU-6 is an attractive chemotherapeutic agent to be developed.
- 14 October 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (5) , 1899-1907
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities
ZJU-6 was designed to enhance anti-angiogenesis and anti-tumour activity of its parent compound Erianin, a clinic anti-tumour agent. This study investigated the detailed biological mechanism of ZJU-6 in comparison with that of Erianin. Both ZJU-6 and Erianin substantially reduced cell viability and induced apoptosis in human cancer cell lines. Profound G2/M cell arrest was observed 24 h after treatment of MCF-7 cells with ZJU-6 (≥ 2.5 μM) or Erianin (≥ 0.1 μM); being consistent with mitotic collapse. 0.5 μM of Erianin or ZJU-6 failed to stabilise tubulin. Pre-G1 MCF-7 cell accumulating 24 h post treatment indicated apoptosis. Caspase-3 activity, PARP cleavage and Annexin V + ve /PI -ve populations correlate the apoptotic destiny of cells exposed to either ZJU-6 or Erianin. Furthermore ZJU-6 showed potent anti-angiogenetic property and demonstrated radical scavenging capacity. Due to its potent anti-proliferative, pro-apoptotic and anti-angiogenic activities ZJU-6 is an attractive chemotherapeutic agent to be developed.
- 18 February 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (3) , 889-897
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83
Cancer is regarded as a proliferative disorder. Inhibition of cyclin-dependent kinases (CDKs), which are the key regulators of the cell-cycle and RNA transcription, represents an attractive strategy for cancer therapy. In this study, we report the cellular mechanistic investigation of CDKI-83, a K i-nanomolar CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 2/M phase with CDKI-83 treatment, phosphorylation at Thr320 of PP1α was significantly reduced, indicating CDK1 inhibition. Importantly, this compound reduced phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulated Mcl-1 and Bcl-2. These results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent.
- 18 February 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (3) , 889-897
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83
Cancer is regarded as a proliferative disorder. Inhibition of cyclin-dependent kinases (CDKs), which are the key regulators of the cell-cycle and RNA transcription, represents an attractive strategy for cancer therapy. In this study, we report the cellular mechanistic investigation of CDKI-83, a K i-nanomolar CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 2/M phase with CDKI-83 treatment, phosphorylation at Thr320 of PP1α was significantly reduced, indicating CDK1 inhibition. Importantly, this compound reduced phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulated Mcl-1 and Bcl-2. These results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent.
- 1 June 2008
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 29 (6) , 302-313
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- 1 June 2008
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 29 (6) , 302-313
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- 1 May 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (10) , 2628-2631
Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin
- 1 May 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (10) , 2628-2631
Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin